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Subarachnoid haemorrhageBackground: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor approved by
the United States Food and Drug Administration for the treatment of various cancers including refractory high
grade glioma. There are case reports of subarachnoid haemorrhage (SAH) during bevacizumab treatment
though the causative role of the drug in these cases has been obscured by the presence of alternative
aetiologies or incomplete investigation. Furthermore, there is no consensus regarding the risk of Central
Nervous System (CNS) haemorrhage during bevacizumab treatment due to limited available study data. Case
Description: A 53 year old female with recurrent gliosarcoma refractory to standard, temozolamide based
chemo-radiotherapy presented to our facility in a post-ictal state 16 days after her second dose of intravenous
bevacizumab. A Fisher grade III SAH was found on computerised tomography scanning with no causative
vascular lesion found on two subsequent digital subtraction angiograms separated by a 10 day period and a
Magnetic Resonance Imaging (MRI) scan 20 days post-bleed. Given the resolution of symptoms over an
uncomplicated 13 day admission, she was discharged home with bevacizumab ceased prior to her scheduled
third dose. Conclusion: We discuss here a case of diffuse, non-traumatic SAH during bevacizumab treatment
of recurrent gliosarcoma in which alternative aetiologies of haemorrhage were excluded, to our knowledge
the ﬁrst such case in the English language literature. This adverse event is compatible with the known
molecular mechanisms of bevacizumab and clinicians should be cognisant of the potential risk of CNS
haemorrhage until larger studies are available to quantify this risk.
Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bevacizumab is a recombinant monoclonal antibody against
vascular endothelial growth factor (VEGF) approved by the United
States Food and Drug Administration (FDA) for use against various
cancers including high grade glioma (HGG) [1,2]. There are published
case reports of subarachnoid haemorrhage (SAH), occasionally with
diffuse vasospasm in patients undergoing bevacizumab therapy [1–4]
though the causative role of the drug in these cases has been obscured
by the presence of alternative aetiologies and incomplete cerebro-
vascular investigation [1,3]. Currently there is no consensus regarding
the risk of Central Nervous System (CNS) haemorrhage duringigital subtraction angiogram;
oma; MRI, magnetic resonance
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ier B.V. This is an open access articlebevacizumab treatment with disagreement between early observa-
tional studies and systematic reviews and more recent pooled
analyses [5,6]. We describe here a case of diffuse, non-traumatic,
non-aneurysmal SAH during bevacizumab treatment of HGG with no
apparent aetiology other than the use of bevacizumab; to our
knowledge the ﬁrst such report in the English language literature.
Case report
A 53 year old female with recurrent gliosarcoma presented to the
Emergency Department of our institution following several witnessed
generalised seizures. She had experienced worsening headaches and
vomiting in the preceding days. There was no history of recent head
injury. The primary tumour was located in the left parietal region and
an initial uncomplicated resection had been performed 11 months
previously. Despite the initiation of standard temozolamide based
chemo-radiotherapy, the tumour had recurred with new foci seen
surrounding the resection cavity and extending posteriorly into the
left occipital lobe. This had prompted an uncomplicated second
resection procedure 10 weeks prior to the acute presentation. The
patient was then commenced on three weekly doses of 800 mgunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) Axial T2-weighted magnetic resonance imaging (MRI) scan obtained before initiation of bevacizumab, 7 weeks prior to acute subarachnoid haemorrhage showing the
resection cavity with evidence of chronic haemorrhage centrally (white arrow). (B) Coronal T1-weighted MRI with intravenous gadolinium contrast performed simultaneously with
previous scan showing aforementioned ﬁndings and residual enhancing tumour medial to occipital horn of left lateral ventricle (black arrow) and anterolateral to the margin of the
resection cavity (white arrow) with normal enhancement of the surrounding intracranial vasculature. (C) Coronal non-contrast computerised tomography (CT) scan obtained
5 weeks prior to acute subarachnoid haemorrhage showing a shallow extra-axial haematoma above the resection cavity (grey arrow) andminor surrounding vasogenic oedemawith
no evidence of acute haemorrhage into the resection cavity. (D) Axial CT with intravenous contrast showing Fisher Grade III subarachnoid haemorrhage with blood in the basal and
suprasellar cisterns, interhemispheric and sylvian ﬁssures extending to the sulci of the anterior left frontal lobe. (E) Para-sagittal view of same scan showing the chronic shallow
extra-axial haematoma overlying the resection cavity (grey arrow) distant to acute subarachnoid haemorrhage visible in the stem of the left sylvian ﬁssure surrounding the left
middle cerebral artery (black arrow). (F) Coronal view of same scan showing the decreased size of resection cavity and overlying shallow extra-axial haematoma since previous
imaging (grey arrow) with no evidence of regional contrast enhancement or haemorrhage into or around the resection cavity.
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16 days previously. A magnetic resonance imaging (MRI) scan was
obtained before the initiation of bevacizumab and showed residual
foci of tumour and chronic haemorrhage into the centre of the
resection cavity as expected post-operatively with no signs of active
bleeding [Fig. 1 A, B]. She was not on anticoagulant or antiplatelet
medication. There was no history of hypertension, a bleeding
diathesis or tobacco, alcohol or recreational drug use.
Initial physical examination was remarkable for a blood pressure of
150/110 mmHg. The Glasgow Coma Score was 13/15 with eye opening
to speechanddisorientationbut improved to 15/15 following resolution
of the post-ictal phase. There were no focal neurological deﬁcits. Initial
laboratory investigations revealed a mildly reduced platelet count of
132× 109/L though this was unchanged over the preceding 3 months.
All other cell counts and routine coagulation studieswerewithinnormal
limits. A computerised tomography angiogram showed a Fisher grade III
SAH positioned centrally, a reduction in the size of the more laterally
located resection cavitywith stable appearances of an overlying shallow
chronic extra-axial collection [Fig. 1C, D, E, F]. There was no evidence of
acute haemorrhage into or around the resection cavity compared to
imaging performed 5 weeks previously [Fig. 1C, D, E, F]. On subsequent
digital subtraction angiography (DSA) no causative intracranial vascular
lesion was identiﬁed but an incidental ﬁnding of an irregular, mild left
cervical segment internal carotid artery (ICA) stenosis was noted.
[Fig. 2A, B] This was thought to most likely represent accelerated
atherosclerosis though acute-on-chronic dissection could not
be excluded.The patient had an uncomplicated 13 day admission. A transient
elevation in mean blood ﬂow velocities by transcranial Doppler
ultrasonography in the middle cerebral arteries was noted on daily
monitoring, peaking at 160 cm/s bilaterally with corresponding
Lindegaard Ratios of 4.1 and 3.3 for the left and right sides respectively
though with no evidence of an ischaemic neurological deﬁcit. Repeat
DSA performed at day 10 was also unremarkable and demonstrated
the stability of the focal left cervical ICA stenosis most likely to be an
old non-ﬂow limiting dissection [Fig. 2D, E, F]. The patient was
subsequently discharged and in light of the inpatient admission,
bevacizumab therapy was discontinued prior to the scheduled third
dose by the treating neuro-oncology team. A repeat MRI obtained six
days later showed complete resolution of SAH with no evidence of a
causative vascular lesion and expected evolution of the resection
cavity [Fig. 3A, B]. No further episodes of CNS haemorrhage occurred
prior to the patient’s death approximately 2 months later due to
tumour progression.
Discussion
In this patient with diffuse, non-traumatic SAH during bevacizumab
therapy, haemorrhage could be reasonably linked to the use of
bevacizumab due to the exclusion of all other potential causes. CNS
haemorrhage due to glial series tumours is almost exclusively
intra-parenchymal in nature, rarely presenting as an isolated diffuse
SAH [7]. In the handful of cases in which a malignant glioma has
presented in thismanner, the tumour has been in close proximity to the
Fig. 2. (A) Digital subtraction angiography (DSA) following left common carotid artery injection, 90° right anterior oblique view on post-bleed day 1 showing an irregularly
contoured left internal carotid artery (ICA) stenosis distal to the bulb (black arrow), no evidence of aneurysm, malformation or ﬁstula and normal vessel calibre throughout. (B) 45°
left anterior oblique view of the same. (C) Anteroposterior view of the same. (D) DSA following left ICA injection, lateral view on post-bleed day 10 showing the same non-ﬂow
limiting stenotic lesion (black arrow)with no aneurysm, ﬁstula or malformation and normal vessel calibre throughout. (E) Anteroposterior view of the same. (F) DSA following right
ICA injection, anteroposterior view on post-bleed day 10 showing normal appearances of the right-sided intracranial vasculature.
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In this case, as the haematoma was centrally located in the suprasellar
and basal cisterns, distant to tumour foci in the left parieto-occipital lobe
where there was also no acute haemorrhage seen on serial neuroim-
aging, intra-tumoural or peri-tumoural haemorrhage was thought to
inadequately account for our patient’s condition. In the setting of diffuse,
non-traumatic SAH, serial negative DSA separated by a 1 week period
post-ictus as undertaken in this case is estimated to be 90%–93%Fig. 3. (A) Axial T2-weighted magnetic resonance imaging (MRI) scan obtained 20 days afte
(white arrow) with a reduction in size and no evidence of interval haemorrhage into or arou
intravenous gadolinium contrast performed simultaneously showing the aforementioned ﬁ
tumour, no new areas of parenchymal contrast enhancement and normal enhancement ofaccurate in the exclusion of a causative vascular lesion [8]. Factorswhich
contribute to false negatives on serial DSA include persistent radio-
graphic vasospasm and the delayed resorption of subarachnoid blood
[8]. As we did not encounter such factors, the second negative
angiogram was deemed sufﬁcient to also exclude a structural vascular
lesion. An angiographically occult vascular malformation, a rare but
important cause of non-aneurysmal SAH could also be excluded due to
its absence on the delayed post-bleed MRI scan. Given the absence ofr acute subarachnoid haemorrhage showing expected evolution of the resection cavity
nd the resection cavity since the previous MRI scan. (B) Coronal T1-weighted MRI with
ndings (white arrow), interval reduction in the size of enhancing nodules of residual
the surrounding intracranial vasculature.
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coagulopathy and antecedent trauma, SAH could be conﬁdently
attributed to bevacizumab therapy.
Between 1997 and 2009, 18 cases of SAH during bevacizumab
treatment were recorded in the United States FDA MedWatch
database; though the indication for therapy and the presence of
alternative aetiologies of haemorrhage in these cases have not been
detailed [2]. There are also two published reports of SAH in patients
undergoing bevacizumab treatment of HGG but in each an alternative
aetiology for haemorrhage is clearly described including trauma [1]
and multiple aneurysms [3]. In another case, Baizabal-Carvallo et al.
reported a non-traumatic, pre-truncal (perimesencephalic) SAH
during bevacizumab treatment of colorectal cancer but only used a
single magnetic resonance angiogram to exclude an aneurysmal cause
[4] despite the established insensitivity of this imaging modality for
this purpose [8]. Thus to our knowledge, this case represents the ﬁrst
report in the English language literature of diffuse, non-traumatic SAH
during bevacizumab treatment of HGG in which all alternative causes
were deﬁnitively excluded.
There are plausible molecular mechanisms accounting for VEGF
blockade with bevacizumab causing diffuse, non-traumatic, non-
aneurysmal SAH. In addition to stimulating angiogenesis, VEGF is also
thought to be a physiological mediator of vascular integrity [6,9].
Putative protective actions include the up-regulation of pro-survival
and anti-apoptotic intracellular signalling pathways within vascular
endothelial cells together with stimulation of nitric oxide and
prostacyclin production causing decreased atherosclerotic vessel
wall injury [6,9]. VEGF blockade with bevacizumab may in turn
promote the formation of defects in the vessel wall [9,10]. The
reduced production of nitric oxide in the vascular endothelium due to
bevacizumab is also known to promote arteriolar vasoconstriction
with increased peripheral vascular resistance sufﬁcient to cause
systemic hypertension [9]. It is then conceivable that this combination
of vessel wall defects and arterial hypertension may directly lead to
haemorrhage from the small-calibre arteries of the cerebral vascula-
ture with consequent diffuse SAH in the absence of trauma or
structural vascular abnormalities. Drug induced vasoconstriction may
also account for the bilateral elevation in mean middle cerebral artery
blood ﬂow velocities seen in this and other cases of SAH while on
bevacizumab [4].
Notably, there is currently no consensus regarding an increased
risk of CNS haemorrhage attributable to bevacizumab therapy [6]. A
number of early studies including systematic reviews of phase II trials
and a single-centre cohort study found a low rate of CNS haemorrhage
among cancer patients treated with bevacizumab, similar to the rate
in patients on standard treatment [5]. However, the estimated risk of
haemorrhage from these studies was inherently limited by their
retrospective non-randomised designs and the small and selected
nature of study populations. The best available evidence is from a
recent meta-analysis of cerebrovascular events in 16 phase II/III
randomised controlled trials of bevacizumab [6]. Based on a subgroup
analysis of 6163 patients enrolled across 7 included studies which
reported the rate of CNS haemorrhage, the overall relative risk of CNShaemorrhage due to bevacizumab treatment was 3.09 (95% CI 1.36–
6.99) [6]. Notably, over 50% of patients included in this subgroup
analysis had newly diagnosed glioblastoma and were participants of a
single phase III randomised placebo controlled trial in which the
relative risk of CNS haemorrhage in the bevacizumab arm was 2.20
(95% CI 0.68–7.08) which approached but did not reach statistical
signiﬁcance [6]. Also, the meta-analysis did not include the other
major trial of bevacizumab therapy for newly diagnosed glioblastoma
RTOG 0825 where in contrast, there was no difference in the rates of
‘haemorrhage’ or ‘serious haemorrhage’ between arms, though the
rate of CNS haemorrhage was not speciﬁed [10].
Conclusion
We report the ﬁrst case of diffuse, non-traumatic subarachnoid
haemorrhage in a patient undergoing bevacizumab treatment for
HGG with no other cause evident despite rigorous investigation.
Whilst there is currently no consensus regarding an increased risk of
CNS haemorrhage attributable to the use of bevacizumab, an
increasing number of studies together with the presence of plausible
molecular mechanisms strongly suggest this to be the case. In our
opinion, routine cerebrovascular investigation with digital subtrac-
tion angiography should be considered in the workup of all
bevacizumab treated patients presenting with diffuse SAH though as
illustrated in this case, such investigation may not yield a causative
structural vascular lesion. Future phase III trials of bevacizumab
together with further post-marketing surveillance are awaited to
conﬁrm and quantify the risk of this putative adverse event.
References
[1] Lukas RV, Goldenberg F, Nicholas MK. Bevacizumab for glioblastoma multiforme
after traumatic subarachnoid hemorrhage. J Clin Neurosci 2012;19:1310–1.
[2] Letarte N, Bressler LR, Villano JL. Bevacizumab and central nervous system (CNS)
hemorrhage. Cancer Chemother Pharmacol 2013;71:1561–5.
[3] Faraji AH, Engh JA, Horowitz M, Lunsford LD, Park DM. Multiple discrete
aneurysmal subarachnoid hemorrhages during multimodality management of a
hypothalamic glioma—case report. Clin Neurol Neurosurg 2013;115:632–5.
[4] Baizabal-Carvallo JF, Alonso-Juarez M, Salas I. Pretruncal subarachnoid hemor-
rhage and high cerebral blood ﬂow velocities with bevacizumab therapy. Clin
Neuropharmacol 2010;33:268–9.
[5] Khasraw M, Holodny A, Goldlust SA, DeAngelis LM. Intracranial hemorrhage in
patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering
experience. Ann Oncol 2012;23:458–63.
[6] Zuo P-Y, Chen X-L, Liu Y-W, Xiao C-L, Liu C-Y. Increased risk of cerebrovascular
events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS
ONE 2014;9(7):e102484. http://dx.doi.org/10.1371/journal.pone.0102484.
[7] Hakan T, Türk CÇ, Çelik H. Intra-operative real time intracranial subarachnoid
haemorrhage during glial tumour resection: a case report. Cases J 2008;1:306.
http://dx.doi.org/10.1186/1757-1626-1-306.
[8] Dalyai R, Chalouhi N, Theofanis T, Jabbour PM, Dumont AS, Gonzalez LF, et al.
Subarachnoid hemorrhage with negative initial catheter angiography: a review of
254 cases evaluating patient clinical outcome and efﬁcacy of short- and long-term
repeat angiography. Neurosurgery 2013;72:646–52 [discussion 51–2].
[9] Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for
cancer. Br J Cancer 2007;96:1788–95.
[10] Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA,
et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl
J Med 2014;370:699–708.
